Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients by Rosen, Richard et al.
Urinary 6-sulfatoxymelatonin level in age-related macular
degeneration patients
Richard Rosen,1,4 Dan-Ning Hu,1,2,4 Violete Perez,1 Katy Tai,1 Guo-Pei Yu,3,4 Min Chen,1,2,4 Paul Tone,5
Steven A. McCormick,1,2,4 Joseph Walsh1,4
1Department of Ophthalmology, New York Eye and Ear Infirmary, New York, NY; 2Department of Pathology, New York Eye and
Ear Infirmary, New York, NY; 3Department of Biostatistics and Epidemiology Service, New York Eye and Ear Infirmary, New York,
NY; 4Departments of Ophthalmology and Otorhinolaryngology, New York Medical College, Valhalla, NY; 5Department of Medicine,
Richmond University Medical Center, Staten Island, NY
Purpose: Melatonin is a potent antioxidant and free radical scavenger. It has been reported that serum melatonin level is
relevant to certain aging diseases. The purpose of this study was to investigate melatonin levels in age-related macular
degeneration (AMD) patients by measurement of 6-sulfatoxymelatonin levels (aMT6s), the major metabolite of melatonin
in urine, and compare it with a group of age- and gender-matched controls.
Methods: The first urine of the morning was collected from 43 AMD patients and 12 controls who did not have AMD.
The level of aMT6s in specimens was measured by a commercial 6-sulfatoxymelatonin ELISA kit. The assay was
performed by researchers, who were masked to the clinical information. To adjust for variation in the diluteness of urine,
urinary creatinine level was measured and aMT6s levels were expressed as aMT6s/creatinine.
Results:  The  level  of  urinary  aMT6s/creatinine  (mean±SD)  in  AMD  (6.24±3.45  ng  aMT6s/mg  creatinine)  was
significantly lower than that of the controls (10.40±4.51, p=0.0128). After adjustment for various factors (age, smoking,
cancer, and coronary heart disease) that may influence the aMT6s level, the odds-ratio of urinary aMT6s comparing AMD
patients to controls was 0.65 (95% confidence interval=0.48–0.88, p=0.0036), indicating that urinary aMT6s level in AMD
patients was lower than in controls even after multivariate adjustment.
Conclusions: Urinary aMT6s level in AMD patients was 40% lower than in age- and gender-matched controls. This
difference between AMD patients and controls is present after adjustment for the factors of age, smoking, and histories
of cancer and coronary heart disease. The significance of this result and the role of melatonin in the occurrence of AMD
require further investigation.
Melatonin, a neurohormone, is mainly produced in the
pineal gland. Melatonin is involved in control of circadian
rhythms  (including  sleep-wake  cycle  and  other  biologic
rhythms), regulation of various physiologic functions, e.g.,
cardiovascular system, immune system, the aging process, etc
[1-4]. Physiologic and pharmacological doses of melatonin
are effective as an antioxidant and free radical scavenger
[4-12]. Results have been published indicating that melatonin
displays  antioxidant  capacity  in  several  experimental
conditions [4,9-22]. It has been reported that blood and urinary
melatonin  levels  decrease  with  age,  and  a  decrease  of
circulating melatonin has been reported in patients with age-
related diseases, e.g., several types of cancer, coronary artery
disease, Alzheimer disease, etc [2,4,23-41].
Age-related macular degeneration (AMD) is the leading
cause of blindness in elderly persons in the western countries.
Oxidative  stress,  the  cellular  damage  caused  by  reactive
oxygen  species  (ROS),  has  been  implicated  in  the
pathogenesis  of  AMD  [32-45].  Melatonin  is  a  strong
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antioxidant  and  can  induce  the  expression  of  various
antioxidant enzymes by activation of melatonin receptors.
Decrease of melatonin production in aged persons may cause
a reduction of antioxidant activity. Therefore, it may be useful
to study the relationship between melatonin level and the
occurrence of AMD.
Changes of circulatory melatonin level in AMD have not
been reported previously. The purpose of this study was to
examine  the  relationship,  if  any,  between  circulatory
melatonin  level  and  AMD  by  assessing  nocturnal  urinary
excretion of 6-sulphatoxymelatonin (aMT6s, an index of peak
blood  melatonin  concentration)  in  patients  with  AMD.  A
group of age- and gender-matched controls was included. In
addition, the effects of factors that may influence the secretion
of  melatonin  (age,  smoking,  coronary  artery  disease,  and
cancer) in these groups were evaluated carefully to exclude
the possible influence caused by these factors.
METHODS
Subjects: This study included 43 randomly selected AMD
patients (21 males and 22 females) along with 12 age- and
gender-matched individuals (5 males and 7 females) without
AMD, who served as the controls. All individuals had normal
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1673kidney and liver functions by history. Patients were asked
during examination for any history of current or previous liver
or kidney diseases. Excluded were shift workers, individuals
with sleep disorders were excluded; persons who had just
undertaken a long distance flight, or those who had taken oral
supplementation of melatonin within the last two weeks.
The criteria for diagnosis of AMD were the presence of
large drusen (>125 μm), areas of macular geographic atrophy,
pigmentary changes of the retinal pigment epithelium (RPE),
or submacular choroidal neovascularization.
The study protocol was reviewed and approved by the
New  York  Eye  and  Ear  Infirmary  (NYEEI)  Institutional
Review Board (IRB). The study adhered to the Helsinki. All
participants  were  fully  informed  of  the  purpose  and
procedures of this study, and an IRB approved consent was
obtained from all participants before study entry. Participants
were carefully directed to collect urine on mornings following
bright sunny days, which they had spent inside, and to avoid
collection following sunless or overcast days for consistent
environmental effect. Urine was collected at the early morning
and refrigerated before delivery to the laboratory. Samples
were then frozen at −70 °C until analysis.
Measurement of 6-sulphatoxymelatonin and creatinine: The
amount of 6-sulphatoxymelatonin (aMT6s) in nocturnal urine
specimens  was  determined  in  duplicate  by  competitive
enzyme-linked immunosorbent assay (ELISA). The ELISA
kit  was  obtained  from  Buehlmann  Laboratories  AG
(Schoenenbuch, Switzerland). Briefly, diluted urine samples,
controls and aMT6s standards were added to wells pre-coated
with antibody to rabbit immunoglobulin. Biotinylated aMT6s
and rabbit anti- aMT6s antibodies were added too. aMT6s in
the  specimens  and  standards  competed  with  biotinylated
aMT6s for the binding sites of the rabbit anti-aMT6s antibody.
The biotinylated aMT6s-antibody complexes formed were
captured by the antibody to rabbit immunoglobulin pre-coated
on the wells. The plate was shaken at a plate mixer (Labnet,
Woodbridge,  NJ)  for  60  s  at  1,000  rpm.  After  complete
mixture on a plate mixer, the plate was incubated for 3 h at
4 °C. All wells were emptied and washed four times with wash
buffer  provided  in  the  ELISA  kit.  Substrate  solution
containing  hydrogen  peroxide  and  tetramethtlbenzidine  in
citrate buffer was added to the well, mixed and incubated for
15 min at room temperature in the dark. The stop solution was
added, and the absorbance at 450 nm of each well was read
by  a  microplate  reader  (Multiskan  EX,  Thermo,  Vantaa,
Finland). The amount of aMT6s in the urine specimen was
calculated  following  the  manufacturer’s  instructions.  The
sensitivity of the assay was 0.14% and the intra- assay and
inter-assay  precision  were  7.1%  and  11.9%,  respectively.
Assays of aMT6s were performed by researchers who were
masked as to the identity of the patients.
Since  individuals  differ  in  the  volume  of  urine  they
produce, urinary creatinine was also assayed in the present
study using the kinetic Jaffe reaction [46,47]. The creatinine
standard solution and picric acid were obtained from Sigma-
Aldrich (St. Louis, MO). The test results were normalized
using creatinine concentration and expressed as nanograms
aMT6s per mg creatinine.
Statistics:  Fisher’s  exact  test  was  used  to  determine  the
statistical  difference  of  percentages  of  various  variables
between AMD and the controls. Student t-test was used to
examine statistical difference of means of variables between
different groups. An unconditional logistic regression model
was used to measure the odds ratios and 95% confidence
intervals (CI) of urinary aMT6s levels between AMD and the
controls. In this model, patients with AMD were coded as 1
and  controls  were  coded  as  0  for  dependent  variable.  To
control potential confounding factors, we adjusted the odds
ratio by age, and histories of smoking, cancer and coronary
artery disease.
RESULTS
Table 1 shows the demographical and clinical data of AMD
patients and the controls. There was no statistically significant
difference in age (p=0.1682) or gender (p=0.7507) between
AMD patients and the controls. Of the participants with a
history of smoking, no statistically significant difference was
present in the rate of smoking history between AMD patients
and the controls (p=0.1011). No participants were smoking at
the time of this study. One control and four AMD patients had
a  history  of  various  cancers;  there  was  no  statistically
significant difference in prevalence of cancer between AMD
patients and the controls (p=1.000). Two controls and 11
AMD patients had a history of coronary artery disease; the
difference of prevalence of heart disease between these two
groups was not statistically significant (p=0.7079).
The amount of aMT6s in nocturnal urine was 6.24±3.45
ng aMT6/mg creatinine (mean±SD) in AMD patients, which
was 60% of the level in the age- and gender-matched controls
(10.4±4.51 ng/mg). The difference of aMT6 level in nocturnal
urine between AMD patients and the controls was statistically
significant (p=0.0128).
Table 2 shows the unadjusted and adjusted odds ratio and
95%  CI  of  nocturnal  urinary  aMT6s/creatinine  level  as
comparing AMD patients with control individuals. As shown
in the table, the results of unadjusted and adjusted odds ratios
were quite close, which indicates that the factors of age and
histories of smoking, cancer and coronary artery disease did
not significantly affect the effect of nocturnal urinary aMT6s/
creatinine level between AMD patients and controls. After
adjusting  for  age,  and  histories  of  smoking,  cancer  and
coronary artery disease, the level of nocturnal urinary aMT6s
excretion in AMD patients was significantly lower than that
in the controls (adjusted odds ratio=0.65 and 95% CI=0.48–
0.88, p=0.0036).
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less  than  20/400  in  both  eyes.  Urinary  aMT6s  level  was
5.84±2.74  ng  aMT6s/mg  creatinine,  which  was  not
significantly different from those who had vision better than
20/400 (6.29±5.54, p=0.778).
DISCUSSION
The secretion of melatonin by the pineal body is circadian,
with  high  levels  at  night  and  very  low  secretion  during
daylight. The measurement of melatonin secretion requires
drawing blood at different times during the night to measure
plasma melatonin levels. This procedure is inconvenient and
requires hospitalization, which is seldom feasible [48-51].
Collection of the first morning urine and measurement of
melatonin level in the urine makes the collecting procedure
easier. However, only less than 1% of melatonin appears
unaltered in urine; most of melatonin undergoes conversion
to metabolites before appearing in the urine [49]. Circulating
melatonin  undergoes  hepatic  metabolism  to  6-
hydroxymelatonin, which is immediately conjugated to yield
6-sulphatoxymelatonin. This product is then excreted in the
urine  and  accounts  for  more  than  70%  of  the  melatonin
secreted. Concentration of aMT6s in urine is 2–3 orders of
magnitude higher than that of melatonin. Therefore it is very
sensitive and thus no extraction is required [48,49]. It has been
reported that there is a good correlation between nocturnal
urinary aMT6s and plasma melatonin level during the night
[48-55]. To compensate for the variation in the diluteness of
urine, urinary creatinine should be used to standardize the
samples for comparison. aMT6s levels in the urine can then
be expressed as ratio of aMT6s/creatinine [48,52]. Estimation
of  nocturnal  circulating  melatonin  levels  by  measuring
nocturnal  urine  aMT6s/creatinine  is  a  well  established,
reliable, and highly feasible procedure for clinical study. This
procedure has been used widely for the study of melatonin
secretion and its relationship with various physiologic and
pathological situations [24,30,48,52,56-58].
Melatonin levels in AMD patients have not been reported.
The  present  study  compared  the  nocturnal  urine  aMT6s/
creatinine levels in AMD patients to those in a group of age-
matched controls to examine whether AMD was associated
with a greater decrease in melatonin levels than seen in non-
AMD aged individuals.
In the present study, nocturnal urine aMT6s level in AMD
was  significantly  less  than  that  of  age-matched  controls,
suggesting that AMD is associated with a greater decrease of
melatonin than typically seen with the normal aging process.
In both AMD and the controls, some of the individuals had a
history  of  smoking,  cancer,  or  coronary  artery  disease—
TABLE 1. DEMOGRAPHICAL AND CLINICAL DATA OF AGE-RELATED MACULAR DEGENERATION PATIENTS AND CONTROLS
Factors AMD Control p-value
Age 75.8±9.07 73.6±6.80 0.1682
Gender (male/female) 21/22 39940 0.7507
Prior smoking 24/43 (55.8%) 3/12 (25.0%) 0.1011
Cancer history 4/43 (9.3%) 1/12 (9.1%) 1
Coronary heart disease 11/43 (25.6%) 2/12 (16.7%) 0.7079
In both AMD and the controls, some of the individuals had a history of smoking, cancer and coronary artery disease, factors
that may influence the melatonin level. Statistical significance of difference in the percentage or mean of these factors between
AMD and the controls was analyzed by student’s t-test or Fischer’s exact test, respectively. There was no statistically significant
difference in these factors between AMD patients and the controls.
TABLE 2. URINARY 6-SULPHATOXYMELATONIN/CREATININE LEVEL IN AGE-RELATED MACULAR DEGENERATION PATIENTS AND CONTROLS.
Statistical adjustment Odds ratio 95% CI p-value
Not adjusted for any factor 0.72 0.58–0.90 0.004
Adjusted for age only 0.73 0.58–0.91 0.006
Adjusted for smoking history only 0.7 0.53–0.89 0.005
Adjusted for histories of cancer and coronary heart
disease only
0.7 0.55–0.89 0.003
Adjusted for all the above factors 0.65 0.48–0.88 0.005
The odds-ratios and 95% confidence intervals (CI) of urinary aMT6s levels between AMD and the controls were estimated by
an unconditional logistic regression model. To control potential confounding factors, the odds-ratio and CI were adjusted by
age, and histories of smoking, cancer and coronary artery disease using multiple logistic regression model. The difference of
aMT6s level between AMD patients and the controls was still present after adjusting for all these factors, indicating that urinary
aMT6s level in AMD patients is significantly lower than that of the controls.
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1675factors that may influence the melatonin level [1-4,25,26,29,
31]. However, statistical analysis indicates that there was no
significant difference in these factors between AMD patients
and  the  controls.  Furthermore,  adjusted  odds  ratio  using
multiple logistic regression model also documented that the
difference of aMT6s level between AMD patients and the
controls was still present after adjusting for all these factors,
indicating  that  urinary  aMT6s  level  in  AMD  patients  is
significantly lower than that of the controls.
There  are  two  possibilities  in  the  causal-relationship
between the lower melatonin level and AMD. First, AMD
interferes in the production of melatonin, and the pathologic
process in the retina is the cause of low circulating melatonin
levels in AMD. Second, deficiency of melatonin plays a role
in the pathogenesis and is at least one of the risk factors for
AMD.
Melatonin  is  mainly  produced  in  the  pineal  body,
although, aside from ocular tissues, there are other tissues
where  the  production  of  melatonin  has  been  detected
[59-63].  However,  melatonin  produced  in  the  retina  is
principally for local purposes. Locally produced melatonin
may  lead  to  a  relatively  high  melatonin  concentration
surrounding photoreceptors, thus protecting these cells either
via  antioxidant  activity  or  by  activation  of  melatonin
receptors. The amount of melatonin produced in the eye is far
less than that produced in pineal body [60,62,63]. It has been
well documented that the blood melatonin level is derived
exclusively  from  the  pineal  gland  in  mammals  [4,59,61].
Therefore,  it  does  not  seem  possible  that  the  decrease  of
urinary aMT6s is due to the changes of melatonin production
in the AMD eye.
Totally  blind  people  may  lose  synchronization  of
circadian rhythms to day/night cycle [64]. However, AMD
almost never leads to total blindness. In the present series,
none of the AMD patients had lost light perception. In four
patients with vision of both eyes at hand motion to 20/400,
urinary aMT6s levels did not differ from patients with vision
better than 20/400. This indicates that the decrease of urinary
aMT6s in AMD is not caused by the decreased visual acuity.
There  is  growing  evidence  that  cumulative  oxidative
stress could play an important role in the development of
AMD [32-45]. Experimental animal and in vitro studies have
demonstrated that various ROS can cause damage to the RPE,
increase the production of vascular endothelial growth factor
[65], and induce deposits beneath the RPE layer that simulate
the  appearance  of  drusen  [66].  Cumulative  prolonged
oxidative damage at the RPE level may contribute to the
development of certain anatomic changes characteristic of
AMD  [67,68].  Changes  in  blood  antioxidants  and  lipid
peroxidation products have been found in AMD patients [34,
39-43]. A decline of plasma glutathione has been detected in
AMD patients [69,70]. Several randomized controlled clinical
trials found a beneficial effect with dietary supplementation
of antioxidants on the occurrence or progression of AMD
[32,36-38].
Melatonin is a free radical scavenger and antioxidant,
which was first demonstrated by Ianas [71]. Since then there
have been hundreds of publications that demonstrate the free
radical scavenging and antioxidant actions of melatonin both
in  in  vitro  and  in  vivo  studies  [5-12].  Several  melatonin
oxidation  products,  e.g.,  N1-acetyl-N2-formyl  −5-
methoxykynuramine  (AMAK)  and  N1-acetyl-5-
methoxykynuramine  (AMK),  are  also  potent  free  radical
scavengers and antioxidants [4,6]. In addition to the direct
effects,  conjugates  of  melatonin  to  melatonin  membrane
receptors (MT1/2 receptors) can induce the expression of
various  natural  antioxidant  enzymes  or  to  increase  their
activity, e.g., superoxide dismutase, glutathione peroxidase,
glutathione reductase and so forth [4-7,12,72]. Numerous in
vitro and in vivo studies have documented the ability of both
physiologic and pharmacological concentrations of melatonin
to protect various cells against oxidative stress [13-22].
In the retina, melatonin receptors have been detected in
the RPE, photoreceptors, retinal ganglion cells, horizontal
cells and amacrine cells [59]. Melatonin may protect the RPE
and photoreceptors via direct antioxidant activity and also
may induce the expression of various antioxidant enzymes by
activation of melatonin receptors [72-75].
Decreased production of melatonin in AMD relative to
age-matched  controls  demonstrated  in  the  present  study
indicates that deficiency of melatonin may play a role in the
occurrence of AMD. The mechanism of lower melatonin level
in AMD, whether it is determined by genetic or environmental
factors,  is  unknown  and  requires  further  investigation.  In
addition, melatonin can also be produced by ocular cells [59,
60]. Therefore, circulating melatonin level is only one of the
factors determining melatonin levels in the eye.
Melatonin  has  been  reported  to  protect  the  RPE  and
photoreceptors against oxidative processes [73-75]. However,
the results are conflicting, and whether the protective effect
of melatonin on ocular cells was due to a direct antioxidant
effect  or  to  indirect  receptor-mediated  effect  was  not
distinguished.  Therefore,  a  comprehensive  study  of  the
protective effects of melatonin on various ocular cells against
different  oxidative  stresses  and  the  mechanisms  that  are
involved in these processes is required.
Yi et al. reported a clinical trial in which they tested the
effects  of  melatonin  supplementation  for  the  treatment  of
AMD. It was their conclusion that melatonin protected the
retina and delayed progression of macular degeneration [76].
However, this was a nonrandomized controlled study with
only  six  months  of  follow-up.  Furthermore,  it  has  been
reported  that  melatonin  treatment  appears  to  have  a
detrimental effect on photoreceptor cell survival in response
to  bright  light  [77].  Therefore,  the  time  for  melatonin
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organization of a clinical trial.
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